SG11201407603YA - Conjugate of a photosensitiser and chitosan and uses thereof - Google Patents
Conjugate of a photosensitiser and chitosan and uses thereofInfo
- Publication number
- SG11201407603YA SG11201407603YA SG11201407603YA SG11201407603YA SG11201407603YA SG 11201407603Y A SG11201407603Y A SG 11201407603YA SG 11201407603Y A SG11201407603Y A SG 11201407603YA SG 11201407603Y A SG11201407603Y A SG 11201407603YA SG 11201407603Y A SG11201407603Y A SG 11201407603YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- chitosan
- reykjavik
- english
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1208548.6A GB201208548D0 (en) | 2012-05-15 | 2012-05-15 | Compound and method |
| PCT/EP2013/059968 WO2013189663A1 (en) | 2012-05-15 | 2013-05-14 | Conjugate of a photosensitiser and chitosan and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407603YA true SG11201407603YA (en) | 2014-12-30 |
Family
ID=46458880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407603YA SG11201407603YA (en) | 2012-05-15 | 2013-05-14 | Conjugate of a photosensitiser and chitosan and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9901636B2 (es) |
| EP (1) | EP2849791B1 (es) |
| JP (1) | JP6456284B2 (es) |
| KR (2) | KR102269861B1 (es) |
| CN (1) | CN104780941B (es) |
| AU (1) | AU2013279748B2 (es) |
| BR (1) | BR112014028315B1 (es) |
| CA (1) | CA2873259C (es) |
| DK (1) | DK2849791T3 (es) |
| ES (1) | ES2682762T3 (es) |
| GB (1) | GB201208548D0 (es) |
| HK (1) | HK1203850A1 (es) |
| HR (1) | HRP20181276T1 (es) |
| HU (1) | HUE039725T2 (es) |
| IN (1) | IN2014DN09418A (es) |
| MX (1) | MX362237B (es) |
| NZ (1) | NZ630582A (es) |
| PL (1) | PL2849791T3 (es) |
| PT (1) | PT2849791T (es) |
| RU (1) | RU2675830C2 (es) |
| SG (1) | SG11201407603YA (es) |
| SI (1) | SI2849791T1 (es) |
| WO (1) | WO2013189663A1 (es) |
| ZA (1) | ZA201408406B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| AU2014390262B2 (en) | 2014-04-11 | 2020-11-26 | Pci Biotech As | Method of treating melanoma |
| AU2015308345B9 (en) * | 2014-08-28 | 2020-12-24 | Pci Biotech As | Compound and method |
| CN104650259A (zh) * | 2015-01-23 | 2015-05-27 | 广西大学 | 一种纳米孔壳聚糖四(4-磺酸基苯基)金属卟啉微球及其制备方法和使用方法 |
| GB201503776D0 (en) | 2015-03-05 | 2015-04-22 | Pci Biotech As | Compound and method |
| GB201511159D0 (en) | 2015-06-24 | 2015-08-05 | Univ Nottingham | Controlled cell delivery vehicle and treatment of tumours |
| CN108884638B (zh) * | 2016-03-22 | 2021-08-31 | 奥布专科学院 | 作为光学增白剂的多糖衍生物 |
| KR20190013289A (ko) * | 2017-08-01 | 2019-02-11 | 순천대학교 산학협력단 | 수용성 키토산을 포함하는 나노광증감제 |
| GB201801169D0 (en) * | 2018-01-24 | 2018-03-07 | Pci Biotech As | Method |
| CN108892743A (zh) * | 2018-05-28 | 2018-11-27 | 南京工业大学 | 用于光动力抗菌的纳米光敏剂，其制备方法及应用 |
| GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
| CN115399328B (zh) * | 2021-05-27 | 2024-03-22 | 中国科学院化学研究所 | 一种多糖基杀菌材料及其制备方法和应用 |
| GB202115451D0 (en) | 2021-10-27 | 2021-12-08 | Pci Biotech As | Method |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| GB9905911D0 (en) * | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
| JP2002241307A (ja) * | 2001-02-19 | 2002-08-28 | Yasuhiko Tabata | 光増感剤を含有する超音波治療用活性酸素発生剤 |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| GB0415663D0 (en) | 2004-07-13 | 2004-08-18 | Psimei Pharmaceuticals Plc | Compound |
| WO2007023398A2 (en) | 2005-05-16 | 2007-03-01 | Universite De Geneve | Compounds for photochemotherapy |
| JP4287411B2 (ja) * | 2005-07-01 | 2009-07-01 | 株式会社東芝 | 仮想メモリシステムおよび仮想記憶方法 |
| CN101024087A (zh) | 2007-03-28 | 2007-08-29 | 长沙理工大学 | 壳聚糖－多肽－卟啉纳米药物载体及其制备和应用 |
| KR101035269B1 (ko) | 2007-04-23 | 2011-05-26 | 한국과학기술연구원 | 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제 |
| KR20090047872A (ko) | 2007-11-08 | 2009-05-13 | 인제대학교 산학협력단 | 신규 카보하이드레이트 복합 클로린 화합물 및 이의제조방법 |
| WO2009077908A1 (en) | 2007-12-14 | 2009-06-25 | University Of Lausanne | Colloidal particle comprising multivalent cyclic anions |
| KR101076717B1 (ko) | 2008-11-07 | 2011-10-26 | 재단법인대구경북과학기술원 | 광역학 치료용 나노구조체 및 그 제조방법 |
| US20100129432A1 (en) | 2008-11-25 | 2010-05-27 | Taipei Medical University | Microorganism-killing combination |
| KR100918811B1 (ko) | 2009-04-29 | 2009-09-25 | 다이아텍코리아 주식회사 | 클로린 ｅ６-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물 |
| CN101977608A (zh) | 2009-04-29 | 2011-02-16 | 多异亚德韩国株式会社 | 含有二氢卟酚e6-叶酸共轭化合物和壳聚糖的用于癌症治疗的药物组合物 |
| JP5662431B2 (ja) * | 2009-06-12 | 2015-01-28 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 癌の光線力学療法のための標的化されたナノフォトメディスン |
| GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
| KR101228106B1 (ko) | 2010-01-21 | 2013-02-01 | 광주과학기술원 | 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체 |
| KR101250150B1 (ko) * | 2010-10-29 | 2013-04-04 | 가톨릭대학교 산학협력단 | 광역학치료를 위한 고분자-광응답제 접합체 및 이의 제조방법 |
-
2012
- 2012-05-15 GB GBGB1208548.6A patent/GB201208548D0/en not_active Ceased
-
2013
- 2013-05-14 IN IN9418DEN2014 patent/IN2014DN09418A/en unknown
- 2013-05-14 EP EP13725109.6A patent/EP2849791B1/en active Active
- 2013-05-14 BR BR112014028315-0A patent/BR112014028315B1/pt not_active IP Right Cessation
- 2013-05-14 AU AU2013279748A patent/AU2013279748B2/en not_active Ceased
- 2013-05-14 SI SI201331125T patent/SI2849791T1/sl unknown
- 2013-05-14 RU RU2014150569A patent/RU2675830C2/ru active
- 2013-05-14 PL PL13725109T patent/PL2849791T3/pl unknown
- 2013-05-14 KR KR1020207019532A patent/KR102269861B1/ko active IP Right Grant
- 2013-05-14 DK DK13725109.6T patent/DK2849791T3/en active
- 2013-05-14 NZ NZ630582A patent/NZ630582A/en not_active IP Right Cessation
- 2013-05-14 CA CA2873259A patent/CA2873259C/en active Active
- 2013-05-14 PT PT13725109T patent/PT2849791T/pt unknown
- 2013-05-14 MX MX2014013516A patent/MX362237B/es active IP Right Grant
- 2013-05-14 ES ES13725109.6T patent/ES2682762T3/es active Active
- 2013-05-14 SG SG11201407603YA patent/SG11201407603YA/en unknown
- 2013-05-14 WO PCT/EP2013/059968 patent/WO2013189663A1/en active Application Filing
- 2013-05-14 JP JP2015512042A patent/JP6456284B2/ja active Active
- 2013-05-14 CN CN201380037602.8A patent/CN104780941B/zh active Active
- 2013-05-14 KR KR1020147035218A patent/KR20150013803A/ko active Application Filing
- 2013-05-14 US US14/401,215 patent/US9901636B2/en active Active
- 2013-05-14 HU HUE13725109A patent/HUE039725T2/hu unknown
-
2014
- 2014-11-17 ZA ZA2014/08406A patent/ZA201408406B/en unknown
-
2015
- 2015-05-18 HK HK15104699.9A patent/HK1203850A1/xx not_active IP Right Cessation
-
2018
- 2018-08-09 HR HRP20181276TT patent/HRP20181276T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407603YA (en) | Conjugate of a photosensitiser and chitosan and uses thereof | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201808214TA (en) | Pyrazolopyrimidine derivatives | |
| SG11201807652SA (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| SG11201804117XA (en) | Neural cell extracellular vessicles | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201900699QA (en) | Drug conjugates with self-stabilizing linkers having improved physiochemical properties | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201908652QA (en) | Pharmaceutical compositions | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201909841RA (en) | Antitumoral compounds |